Deep Learning Approaches and Applications in Toxicologic Histopathology: Current Status and Future Perspectives

por Mehrvar, Shima, Himmel, Lauren E., Babburi, Pradeep, Goldberg, Andrew L., Guffroy, Magali, Janardhan, Kyathanahalli, Krempley, Amanda L., Bawa, Bhupinder
Publicado 2021

Selective inhibition of integrin αvβ6 leads to rapid induction of urinary bladder tumors in cynomolgus macaques

por Guffroy, Magali, Trela, Bruce, Kambara, Takahito, Stawski, Lukasz, Chen, Huidong, Luus, Lia, Montesinos, Monica S, Olson, Lauren, He, Yupeng, Maisonave, Kevin, Carr, Tracy, Lu, Min, Ray, Adrian S, Hazelwood, Lisa A
Publicado 2022

Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors

por Zhong, Wenyan, Myers, Jeremy S., Wang, Fang, Wang, Kai, Lucas, Justin, Rosfjord, Edward, Lucas, Judy, Hooper, Andrea T., Yang, Sharon, Lemon, Lu Anna, Guffroy, Magali, May, Chad, Bienkowska, Jadwiga R., Rejto, Paul A.
Publicado 2020

NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells

por Geles, Kenneth G., Gao, Yijie, Giannakou, Andreas, Sridharan, Latha, Yamin, Ting-Ting, Zhang, Jing, Karim, Riyez, Bard, Joel, Piche-Nicholas, Nicole, Charati, Manoj, Maderna, Andreas, Lucas, Judy, Golas, Jonathon, Guffroy, Magali, Pirie-Shepherd, Steven, Roy, Marc, Qian, Jessie, Franks, Tania, Zhong, Wenyan, O’Donnell, Christopher J., Tchistiakova, Lioudmila, Gerber, Hans-Peter, Sapra, Puja
Publicado 2021

Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

por Hooper, Andrea T., Marquette, Kimberly, Chang, Chao-Pei Betty, Golas, Jonathon, Jain, Sadhana, Lam, My-Hanh, Guffroy, Magali, Leal, Mauricio, Falahatpisheh, Hadi, Mathur, Divya, Chen, Ting, Kelleher, Kerry, Khandke, Kiran, Muszynska, Elwira, Loganzo, Frank, Rosfjord, Edward, Lucas, Judy, Kan, Zhengyan, Subramanyam, Chakrapani, O'Donnell, Christopher, Neri, Dario, Gerber, Hans-Peter, May, Chad, Sapra, Puja
Publicado 2022

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

por Baumgartner, Christina K., Ebrahimi-Nik, Hakimeh, Iracheta-Vellve, Arvin, Hamel, Keith M., Olander, Kira E., Davis, Thomas G. R., McGuire, Kathleen A., Halvorsen, Geoff T., Avila, Omar I., Patel, Chirag H., Kim, Sarah Y., Kammula, Ashwin V., Muscato, Audrey J., Halliwill, Kyle, Geda, Prasanthi, Klinge, Kelly L., Xiong, Zhaoming, Duggan, Ryan, Mu, Liang, Yeary, Mitchell D., Patti, James C., Balon, Tyler M., Mathew, Rebecca, Backus, Carey, Kennedy, Domenick E., Chen, Angeline, Longenecker, Kenton, Klahn, Joseph T., Hrusch, Cara L., Krishnan, Navasona, Hutchins, Charles W., Dunning, Jax P., Bulic, Marinka, Tiwari, Payal, Colvin, Kayla J., Chuong, Cun Lan, Kohnle, Ian C., Rees, Matthew G., Boghossian, Andrew, Ronan, Melissa, Roth, Jennifer A., Wu, Meng-Ju, Suermondt, Juliette S. M. T., Knudsen, Nelson H., Cheruiyot, Collins K., Sen, Debattama R., Griffin, Gabriel K., Golub, Todd R., El-Bardeesy, Nabeel, Decker, Joshua H., Yang, Yi, Guffroy, Magali, Fossey, Stacey, Trusk, Patricia, Sun, Im-Meng, Liu, Yue, Qiu, Wei, Sun, Qi, Paddock, Marcia N., Farney, Elliot P., Matulenko, Mark A., Beauregard, Clay, Frost, Jennifer M., Yates, Kathleen B., Kym, Philip R., Manguso, Robert T.
Publicado 2023